Supplementary Materials

Supplementary Materials 1. Clinical parameters

Table 1 reports the comprehensive list of clinical variables to be collected for both prospective and retrospective patients. Specifically, the relevant variables for the Impella and ECMO groups are specified, along with the timing for measurements during the observation period.

	Target	patients	Timing of measurement		
Patients' characteristics	Impella group	ECMO group	T0 (Baseline)		
Age (years)	X	X	X		
Sex (male/female)	X	X	X		
BMI (kg/m2)	X	X	X		
Arterial Hypertension (yes/no)	X	X	X		
Diabetes Mellitus (yes/no)	X	X	X		
Chronic kidney disease (yes/no)	X	X	X		
Peripheral artery disease(yes/no)	X	X	X		
ICD/CRT (yes/no)	X	X	X		
Previous PTCA (yes/no)	X	X	X		
Previous CABG (yes/no)	X	X	X		
Chronic heart failure (yes/no)	X	X	X		
Cause of acute heart failure:					
*Acute coronary syndrome (yes/no)	X	X	X		
*Myocarditis (yes/no)	X	X	X		
*End stage dilatative cardiomyopathy (yes/no)	X	X	X		
*Arrhythmia/ arrhythmic storm(yes/no)	X	X	X		
*Other (specify)	X	X	X		
Phenotype of cardiogenic shock:					
* LV dominant (yes/no)	X	X	X		
*RV isolated (yes/no)	X	X	X		
* Biventricular failure(yes/no)	X	X	X		
Onset of shock (hours)	X	X	X		
Hemodynamic presentation of shock:					
* Wet and cold (classic CS) (yes/no)	X	X	X		

- t- W				T	1	1
* Wet and warm (vasodilatory CS) (yes/no)	X	X	X			
* Dry and cold (euvolemic CS) (yes/no)	X	X	X			
Revascularization procedure with stent implantation (yes/no)	X	X	X			
Cardiac arrest(yes/no)	X	X	X			
eGFR (ml/min/m2)	X	X	X			
AKI requiring CRRT yes/no)	X	X	X			
Mechanical ventilation yes/no)	X	X	X			
Days of mechanical ventilation yes/no)	X	X	X			
Mortality risk score	Impella group	ECMO group	T0 (Baseline)			
NYHA	X	X	X			
INTERMACS score	X	X	X			
SCAI class	X	X	X			
CARDshock score (see below)	X	X	X			
RESCUE SCORE	X	X	X			
SAVE score	X	X	X			
MCS strategy and data	Impella	ЕСМО	Event (Y/N)			
	group	group				
Lumbantation matheman		8 - 1				
Implantation pathway:	V		V			
* MCS escalation (yes/no)	X	X	X			
* MCS escalation (yes/no) * MCS de-escalation (yes/no)	X	X	X			
* MCS escalation (yes/no) * MCS de-escalation (yes/no) * First support (yes/no)		X				
* MCS escalation (yes/no) * MCS de-escalation (yes/no)	X	X	X			
* MCS escalation (yes/no) * MCS de-escalation (yes/no) * First support (yes/no) Device implantation pre PCI	X X	X X X	X X			
* MCS escalation (yes/no) * MCS de-escalation (yes/no) * First support (yes/no) Device implantation pre PCI (yes/no) Device implantation post PCI	X X X	X X X	X X X			
* MCS escalation (yes/no) * MCS de-escalation (yes/no) * First support (yes/no) Device implantation pre PCI (yes/no) Device implantation post PCI (yes/no)	X X X	X X X	X X X			
* MCS escalation (yes/no) * MCS de-escalation (yes/no) * First support (yes/no) Device implantation pre PCI (yes/no) Device implantation post PCI (yes/no) Implantation strategy¹:	X X X	X X X X	X X X			
* MCS escalation (yes/no) * MCS de-escalation (yes/no) * First support (yes/no) Device implantation pre PCI (yes/no) Device implantation post PCI (yes/no) Implantation strategy¹: * Bridge to recovery (yes/no)	X X X	X X X X	X X X			
* MCS escalation (yes/no) * MCS de-escalation (yes/no) * First support (yes/no) Device implantation pre PCI (yes/no) Device implantation post PCI (yes/no) Implantation strategy¹: * Bridge to recovery (yes/no) * Bridge to LVAD (yes/no)	X X X X	X X X X X	X X X X			
* MCS escalation (yes/no) * MCS de-escalation (yes/no) * First support (yes/no) Device implantation pre PCI (yes/no) Device implantation post PCI (yes/no) Implantation strategy¹: * Bridge to recovery (yes/no) * Bridge to LVAD (yes/no) * Bridge to transplant (yes/no)	X X X X X X X X	X X X X X X X X X	X X X X X X X X			
* MCS escalation (yes/no) * MCS de-escalation (yes/no) * First support (yes/no) Device implantation pre PCI (yes/no) Device implantation post PCI (yes/no) Implantation strategy¹: * Bridge to recovery (yes/no) * Bridge to LVAD (yes/no) * Bridge to transplant (yes/no) * Bridge to candidacy (yes/no)	X X X X X X X X	X X X X X X X X X	X X X X X X X X			
* MCS escalation (yes/no) * MCS de-escalation (yes/no) * First support (yes/no) Device implantation pre PCI (yes/no) Device implantation post PCI (yes/no) Implantation strategy¹: * Bridge to recovery (yes/no) * Bridge to LVAD (yes/no) * Bridge to transplant (yes/no) * Bridge to candidacy (yes/no) Implantation route:	X X X X X X	X X X X X X X X X	X X X X X X			
* MCS escalation (yes/no) * MCS de-escalation (yes/no) * First support (yes/no) Device implantation pre PCI (yes/no) Device implantation post PCI (yes/no) Implantation strategy¹: * Bridge to recovery (yes/no) * Bridge to LVAD (yes/no) * Bridge to transplant (yes/no) * Bridge to candidacy (yes/no) Implantation route: *Axillar (yes/no)	X X X X X X X	X X X X X X X X X X X X X X X X X X X	X X X X X X X			

Typically reassessed also at the end of the patient journey, as it might be subject to changes from the original plan

2

Need for surgical implant (yes/no)	X	X	X			
Duration of implantation (min)	X	X	Y, minutes			
Hemodinamic and Lab Parameters Trend	Impella group	ECMO group	T0 (Baseline)	24 h post implantation	48-72 h post implantation	First measurement after device removal
Mean arterial pressure (mmHg)	X	X	X	X	X	X
Systolic arterial pressure (mmHg)	X	X	X	X	X	X
Heart rate (bpm)	X	X	X	X	X	X
CVP (mmHg)	X	X	X	X	X	X
CI (l/min/mq)	X	X	X	X	X	X
PCWP (mmHg)	X	X	X	X	X	X
SvO2 (%)	X	X	X	X	X	X
RVSWI (g/m/beat/m ²)	X	X	X	X	X	X
Creatinine (mg/dl)	X	X	X	X	X	X
Lactates (mmol/L)	X	X	X	X	X	X
Troponin (pg/ml)	X	X	X	X	X	X
Inotropic score	X	X	X	X	X	X
NT-proBNP (ng/L)	X	X	X	X	X	X
Platelets (per microliter)	X	X	X	X	X	X
D-dimers (μg/mL)	X	X	X	X	X	X
Bilirubin (mg/dl)	X	X	X	X	X	X
LV EF (%)	X	X	X	X	X	X
RV EF (%)	X	X	X	X	X	X
Mechanical ventilation (yes/no)	X	X	X	X	X	X
Safety in-hosp complications	Impella group	ECMO group	Event during support(yes/no)	Eventual commo	ents/event descrip	otion
Bleeding (and site):						
*Major (yes/no)	X	X				
*Moderate (yes/no)	X	X				
*Minor (yes/no)	X	X				
Bleeding requiring surgery (yes/no)	X	X				
Bleeding from Impella (ECMO insertion site (yes/no)	X	X				
Limb ischemia (yes/no)	X	X				
Vascular complication requiring intervention/surgery (yes/no)	X	X				
Ischemic stroke (yes/no)	X	X				
Device malfunction(yes/no)	X	X				
LV perforation (yes/no)	X					
LV perforation (yes/no)	X					

Mitral valve injury (yes/no)	Aortic valve injury (yes/no)	X				
Lesion to other intracardiac structure (yes/no) aortic dissection (yes/no) AV X X AV X Comparison of MCS support (days) mobilization (chair) with MCS and physiotherapy (yes/no) Major device malfunction (yes/no) AV X X AV X AV X Minor Hemolysis (yes/no) AV X X Sepsis (yes/no) Extracorporeal purification (i.e. Cytosorb) (yes/no) EV X X Extracorporeal purification (i.e. Cytosorb) (yes/no) EV Transfusion, numbers of unit AV X X PFI transfusion, numbers of unit AV X X Device related outcomes Duration of MCS support (days) mobilization (wall) with MCS and physiotherapy (yes/no) Major device malfunction (yes/no) AV X X Reason for device exchange AV X X Reason for device exchange Buryinal and cardine outcomes Outcome malfunction (yes/no) AV X X Reason for device exchange AV X		X				
structure (yes/no) aortic dissection (yes/no) Aortic dissection (yes/no) Najor Hemolysis (yes/no						
Other device related injury (yes/no) Major Hemolysis (yes/no) X X Minor Hemolysis (yes/no) X X Sepsis (yes/no) X X Sepsis (yes/no) Extracorporeal purification (i.e. Cytosorb) (yes/no) Extracorporeal purification (i.e. Cytosorbo) (yes/no) Extracorporeal purification (yes/no) Extracorporeal purifica	structure (yes/no)	X	X			
(yes/no) X X Major Hemolysis (yes/no) X X Milnor Hemolysis (yes/no) X X AKI requiring CRRT (yes/no) X X Sepsis (yes/no) X X Extracorporacl purification (i.e. Cytosorb) (yes/no) C Cytosorb) (yes/no) X X EC transfusion, numbers of unit X X FPF transfusion, numbers of unit X X FPLT transfusion, numbers of unit X X PUT transfusion, numbers of unit X X ECMO group group group group Eventual comments/event description Duration of MCS support (days) X X Duration of MCS support (days) X X Mobilization (walk) with MCS and physiotherapy (yes/no) X X Major device malfunction (yes/no) X X Major device malfunction (yes/no) X X Survival and cardiac outcomes X X Survival and cardiac outcomes X X Survival to next ther	aortic dissection (yes/no)	X	X			
Major Hemolysis (yes/no)	Other device related injury					
Minor Hemolysis (yes/no)	(yes/no)	X	X			
AKI requiring CRRT (yes/no)	Major Hemolysis (yes/no)	X	X			
Sepsis (yes/no)	Minor Hemolysis (yes/no)	X	X			
Extracorporeal purification (i.e. Cytosorb) (yes/no) EC transfusion, numbers of unit	AKI requiring CRRT (yes/no)	X	X			
Cytosorb) (yes/no) EC transfusion, numbers of unit EFP transfusion, numbers of unit FFP transfusion, numbers of unit X X PLT transfusion, numbers of unit X X Device related outcomes Duration of MCS support (days) mobilization (chair) with MCS x X X X Mobilization (walk) with MCS and physiotherapy (yes/no) mobilization (walk) with MCS and physiotherapy (yes/no) Major device malfunction (yes/no) X X X X Device exchange (yes/no) Survival and cardiac outcomes TImpella group TOWN TOWN TOWN TOWN TOWN TOWN TOWN TOWN	Sepsis (yes/no)	X	X			
EC transfusion, numbers of unit FPP transfusion	Extracorporeal purification (i.e.					
FFP transfusion, numbers of unit	Cytosorb) (yes/no)					
PLT transfusion, numbers of unit X	EC transfusion, numbers of unit	X	X			
Device related outcomes Impella group ECMO group Variable group Eventual comments/event description Duration of MCS support (days) X X X mobilization (chair) with MCS and physiotherapy (yes/no) X X Major device malfunction (yes/no) X X Device exchange (yes/no) X X Survival and cardiac outcomes Impella group ECMO group Event (yes/no) Eventual comments/event description 30-day mortality (yes/no) X X Eventual comments/event description 4 X X Eventual comments/event description 5 Eventual comments/event description Eventual comments/event description 6 Event (yes/no) Eventual comments/event description 8 Event (yes/no) Eventual comments/event description 8 Event (yes/no) Eventual comments/event description 8 Event (yes/no) Eventual comments/event description 9 Event (yes/no) Event (yes/no) 1 X X 1 Y X </td <td>FFP transfusion, numbers of unit</td> <td>X</td> <td>X</td> <td></td> <td></td>	FFP transfusion, numbers of unit	X	X			
Duration of MCS support (days) Duration of MCS support (days) Mobilization (chair) with MCS and physiotherapy (yes/no) Major device malfunction (yes/no) Major device exchange (yes/no) Major device exchange (yes/no) Major device exchange (yes/no) Major device exchange	PLT transfusion, numbers of unit	X	X			
Duration of MCS support (days) Nobilization (chair) with MCS and physiotherapy (yes/no) mobilization (walk) with MCS and physiotherapy (yes/no) Major device malfunction (yes/no) Nobilization (walk) with MCS and physiotherapy (yes/no) Major device exchange (yes/no) Nobilization (walk) with MCS and physiotherapy (yes/no) Nobilization (yes/no) Nobilization (walk) with MCS and physiotherapy (yes/no) Nobilization (yes/no)	Device related outcomes	Impella	ECMO	Variable	Eventual comments/event description	
mobilization (chair) with MCS and physiotherapy (yes/no) mobilization (walk) with MCS and physiotherapy (yes/no) Major device malfunction (yes/no) Major device exchange (yes/no) Event (yes/no) Survival and cardiac outcomes Timpella group group group group To Hospital mortality (yes/no) Way and therapy (yes/no) X X X Event (yes/no) X X X Event (yes/no) Eventual comments/event description To Hospital mortality (yes/no) X X X Weaning from MCS (yes/no) X X X Myocardial recovery (yes/no) X X X Bridge to LVAD (yes/no) X X X Cause of death X X X Duration of lCU stay, days Sequelae of hospital complication X X X Survival was a sequelae of hospital complication X X X Survival to next therapy (yes/no) X X X Sequelae of hospital complication X X X Sequelae of hospital complication	201100 Tomoto outcomes	group	group	, m. m.	Sterious commences tent description	
and physiotherapy (yes/no) mobilization (walk) with MCS and physiotherapy (yes/no) Major device malfunction (yes/no) Major device exchange (yes/no) Neason for device exchange Survival and cardiac outcomes Survival and cardiac outcomes Impella group group group Survival to next therapy (yes/no) X X Weaning from MCS (yes/no) X X Weaning from MCS (yes/no) X X Myocardial recovery (yes/no) X X X Middle to LVAD (yes/no) X X Cause of death X X X X X X X X X X X X X		X	X			
mobilization (walk) with MCS and physiotherapy (yes/no) Major device malfunction (yes/no) X X Device exchange (yes/no) X X Reason for device exchange X X Survival and cardiac outcomes Impella group group group group group Wes/no) X X Event (yes/no) Eventual comments/event description Eventual to mments/event description Eventual to mments/event description X X ICU mortality (yes/no) X X Hospital mortality (yes/no) X X Weaning from MCS (yes/no) X X Myocardial recovery (yes/no) X X Bridge to LVAD (yes/no) X X Cause of death X X Duration of ICU stay, days Sequelae of hospital complication X X X		X	X			
hysiotherapy (yes/no) Major device malfunction (yes/no) X X Device exchange (yes/no) X X X Reason for device exchange X X Survival and cardiac outcomes Impella group group group group Beent (yes/no) Event (yes/no) Eventual comments/event description Eventual to memorality (yes/no) X X ICU mortality (yes/no) X X Hospital mortality (yes/no) X X Weaning from MCS (yes/no) X X Myocardial recovery (yes/no) X X Bridge to LVAD (yes/no) X X Cause of death X X Duration of ICU stay, days Sequelae of hospital complication X X X						
Major device malfunction (yes/no) X X X Device exchange (yes/no) X X X Reason for device exchange X X Survival and cardiac outcomes Impella group group group group 30-day mortality (yes/no) X X X ICU mortality (yes/no) X X X Hospital mortality (yes/no) X X X Survival to next therapy (yes/no) X X X Weaning from MCS (yes/no) X X X Myocardial recovery (yes/no) X X X Bridge to LVAD (yes/no) X X X Cause of death X X X Duration of ICU stay, days X X Sequelae of hospital complication X X X Sequelae of hospital complication X X X		X	X			
Device exchange (yes/no)		**	**			
Reason for device exchange X						
Survival and cardiac outcomesImpella groupECMO groupEvent (yes/no)Eventual comments/event description30-day mortality (yes/no)XXICU mortality (yes/no)XXHospital mortality (yes/no)XXSurvival to next therapy (yes/no)XXWeaning from MCS (yes/no)XXMyocardial recovery (yes/no)XXBridge to LVAD (yes/no)XXBridge to Transplant (yes/no)XXCause of deathXXDuration of ICU stay, daysXXSequelae of hospital stay, daysXX						
Survival and cardiac outcomes group	Reason for device exchange					
30-day mortality (yes/no) X X X ICU mortality (yes/no) X X X Hospital mortality (yes/no) X X X Survival to next therapy (yes/no) X X X Weaning from MCS (yes/no) X X X Myocardial recovery (yes/no) X X X Bridge to LVAD (yes/no) X X X Bridge to Transplant (yes/no) X X X Cause of death X X X Duration of ICU stay, days X X Sequelae of hospital stay, days X X Sequelae of hospital complication X X X	Survival and cardiac outcomes	_		Event (yes/no)	Eventual comments/event description	
ICU mortality (yes/no) X X X Hospital mortality (yes/no) X X Survival to next therapy (yes/no) X X Weaning from MCS (yes/no) X X Myocardial recovery (yes/no) X X Bridge to LVAD (yes/no) X X Bridge to Transplant (yes/no) X X Cause of death X X X Duration of ICU stay, days X X Sequelae of hospital stay, days X X Sequelae of hospital complication X X X						
Hospital mortality (yes/no) X X X Survival to next therapy (yes/no) X X X Weaning from MCS (yes/no) X X X Myocardial recovery (yes/no) X X X Bridge to LVAD (yes/no) X X X Bridge to Transplant (yes/no) X X X Cause of death X X X Duration of ICU stay, days X X Sequelae of hospital complication X X X						
Survival to next therapy (yes/no) X X Weaning from MCS (yes/no) X X Myocardial recovery (yes/no) X X Bridge to LVAD (yes/no) X X Bridge to Transplant (yes/no) X X Cause of death X X Duration of ICU stay, days X X Sequelae of hospital complication X X X						
Weaning from MCS (yes/no) X X Myocardial recovery (yes/no) X X Bridge to LVAD (yes/no) X X Bridge to Transplant (yes/no) X X Cause of death X X Duration of ICU stay, days X X Sequelae of hospital complication X X						
Myocardial recovery (yes/no) X X Bridge to LVAD (yes/no) X X Bridge to Transplant (yes/no) X X Cause of death X X Duration of ICU stay, days X X Duration of hospital stay, days X X Sequelae of hospital complication X X X						
Bridge to LVAD (yes/no) X X Bridge to Transplant (yes/no) X X Cause of death X X Duration of ICU stay, days X X Duration of hospital stay, days X X Sequelae of hospital complication X X		X	X			
Bridge to Transplant (yes/no) X X X Cause of death X X X Duration of ICU stay, days X X Duration of hospital stay, days X X Sequelae of hospital complication X X X		X	X			
Cause of death X X Duration of ICU stay, days X X Duration of hospital stay, days X X Sequelae of hospital complication X X	Bridge to LVAD (yes/no)	X	X			
Duration of ICU stay, days X X Duration of hospital stay, days X X Sequelae of hospital complication X X	Bridge to Transplant (yes/no)	X	X	_		
Duration of hospital stay, days X X Sequelae of hospital complication X X	Cause of death	X	X			
Sequelae of hospital complication X X	Duration of ICU stay, days	X	X			
X X	Duration of hospital stay, days	X	X			
at discharge (yes/no)	Sequelae of hospital complication	У	x			
	at discharge (yes/no)	21	- 11			

Details of sequelae	X	X	
Duration of mechanical ventilation(days)	X	X	
Tracheostomy (yes/no)	X	X	
Able to perform self-care at discharge (yes/no)	X	X	
Able to return to work at discharge (yes/no)	X	X	

CARDshock score calculation:

Age > 75 years (yes/no)

Confusion at presentation (yes/no)

Prior myocardial infarction of CABG (yes/no)

Acute coronary syndrome ethology (yes/no)

Blood lactate level (<2/2-4/>4)

eGRF (>60/30-60/<30 ml/min/m2)

To the eCRF section dedicated to DTI, it should be added bivalirudin.

It should be added a section that recaps the types of antibiotics use and the duration of therapy (to estimate costs):

Antibiotic class	Use (yes/no)	Duration of therapy (days)
Cephalosporines (yes/no)		
Pennicillins (yes/no)		
Penicillins (yes/no)		
Glycopeptides (yes/no)		
Fluoroquinolones (yes/no)		
Macrolides (yes/no)		
Carbapenems (yes/no)		
Lyncosamids (yes/no)		
Aminoglicosides (yes/no)		
Tetracyclins (yes/no)		
Sulfonamides (yes/no)		
Oxazolidinones (yes/no)		
Polypeptides (yes/no)		
Other (yes/no) – specify class		
Second line antibiotic therapy needed		
(yes/no)		

Supplementary Material 2. Healthcare resource use variables (hospital data)

The health services performed to follow-up the patients will be measured by recording the number of assessments performed over the study observation period. These data represent the items necessary to determine the direct healthcare costs incurred by the healthcare system which will be included in the Cost Effectiveness Analysis (CEA). These data are normally traced by hospital records (e.g., eHRs, administrative data), and should be only transferred into the Register platform from treating clinicians. These data are not to be asked to patients. These variables will be measured throughout the patient's the hospital stay. In this study, the following data will be recorded by the doctors during the 6-month follow-up period.

Section 1. Hospitalizations

- 1.1 Reason for hospitalization
 - Heart failure: yes/no/unknown + number
 - Ictus ischemic: yes/no/unknown + number
 - Ictus hemorrhagic: yes/no/unknown + number
 - Bleeding: yes/no/unknown + number
 - Renal failure: yes/no/unknown + number
 - Respiratory failure: yes/no/unknown + number
 - Arrhythmia: yes/no/unknown + number
 - Other (please specify): _____ [maximum 5 reasons]
- 1.2 Number of bed-days in regular ward (e.g., cardiac care ward, other): n (units)
- 1.3 Number of days in ICU (i.e., intensive care unit): n (units)
- 1.4 Procedures performed (0 if no procedures are performed)
 - Blood transfusion: yes/no/unknown + number
 - Dialysis: yes/no/unknown + number
 - Ventilatory support: yes/no/unknown + number
 - Surgery: yes/no/unknown + number
 - Type of surgery (qualitative comment)
 - Local interventions: Gastroscopy: yes/no/unknown + number
 - Local interventions: Thoracic drainage: yes/no/unknown + number
 - Local interventions: Endoscopy: yes/no/unknown + number
 - Local interventions: other (please specify name and units):
 - Physiotherapy: yes/no; nr. of weekly cycles: n (units)
 - Ambulatory visit: n (units)

1.5 Exams

- CT Scan: yes/no; n (units)
- MRI: yes/no; n (units)
- Angiography: yes/no; n (units)
- Other (please specify): _____

Section 2: Pharmaceutical consumption during hospitalization

6

2.1 Drugs used

• Antibiotics: yes/no; days on antibiotics (units)

2.2 Medical devices used

- Nr. of Impella devices used (units)
- Nr. of ECMO devices used (units)
- Dialysis: yes/no
- Extracorporeal purification: yes/no
 - o (If yes) Cytosorb: yes/no
 - o (If yes) Other (please specify): yes/no + name
- Other (please specify) _____

Section 3: Emergency department

- ER access for heart failure-related symptoms: yes/no
- ER access with no subsequent hospitalization: yes/no + number
- ER access leading to hospitalization: yes/no + number
- Use of the ambulance services: yes/no

Section 4: Other relevant information

Recovery time needed to go back to work or to "normal life" (from clinician's perspective): 30 days/60 days/120 days/NA

Supplementary Material 3. Patient questionnaire to assess the societal impact of the disease

The following questionnaire will be answered by patients. It has been translated in Italian and will be administered to patients in Italian, however it will be inserted in the Register in English. Both Italian and English versions are provided hereafter. The questionnaire is comprised of two parts:

- A. baseline questionnaire, to be administered at signature of informed consent/at ICU-discharge (typically in-person);
- B. follow-up questionnaire, to be administered at 6 months, typically over the phone.

A. Baseline questionnaire

- 1. Employment status:
- 1.1 What is your current employment status?

If employee:

- factory worker
- employee
- manager, director

If self-employed:

- businessman/woman, freelancer
- other self-employed

If non-professional status:

- retired
- student
- housewife
- other, not employed
- 1.2 If you are a worker, what is your employment status?
- Full time
- Part-time: 20 hours/week
- Part-time: 24 hours/week
- Part-time: 30 hours/week
- Part-time: 36 hours/week
- 2. Travel information:
- 2.1 How much do you spend on average to reach the hospital?

€ _____

- 2.2 How do you typically reach the hospital?
- By car
- By public transport
- By taxi

• Other (specify)

B. Follow-up questionnaire
 Out-of-pocket (OOP) expenses information: In the past 3 months, did you sustain any expense due to cardiogenic shock? Yes No If yes, what where the healthcare expenses related to? Medical care Specialty visits/exams (e.g., second opinion)
Drugs (e.g., non-reimbursable drugs, supplements)
Psychological support
• Other (specify)
1.3 If yes, how much did you spend for each health event? $\begin{array}{c} \varepsilon \\ \underline{\hspace{0.5cm}} \\ \varepsilon \underline{\hspace{0.5cm}} \\ \varepsilon \underline{\hspace{0.5cm}} \end{array}$
 2. Hospitalizations outside the clinical site of study: 2.1 In the past 3 months, were you hospitalized in a different hospital from this one? Yes No
2.2 If yes, please indicate the reason: and the hospitalization duration (days):
 2.3 Did you use emergency services? Emergency department Ambulance None
2.4 Did you pay for any of these services?Yes
• No
2.5 If yes, how much did you spend? € 3. Informal or formal assistance:
3.1 Who gave you informal assistance following your episode of cardiogenic shock? If more than one person, please indicate the one who gives you the most help.No one
• Spouse/cohabitant/partner 9

hospitalizations.

_ days

• Child		
• Parent		
Brother/Sister		
• Friend		
• Other		
3.2 If you indicated that someone assists you, how many days does this persmonth, due to issues related to cardiogenic shock? If you want to indicate half days		
3.3 If you indicated that someone assists you, considering the total time you from this person, please indicate what percentage you are assisted in the follopercentages must make 100%):		
Activities	%	
Nursing activities (eg. drugs administration) and personal care (eg. getting		
dressed, personal washing)		
Daily activities (eg. work, study, house works, family activities, entertainment, travel)		
Psychological support		
1 sychological support		
3.4 In the past 3 months, because of complications following your case of card to paid contractors/workers for household help (e.g., babysitter, domestic help 1. No 2. Yes; How much did you spend?€		
 4. Limitations caused by the pathology: 4.1 In the past 3 months, approximately how many days of work (professional problems related to cardiogenic shock (if half a day, indicate 0.5)? Exclude visits, examinations or hospitalizations. days 		
4.2 In the past 3 months, how many days have you missed out on activities rel life (e.g., going out with friends, hobbies, sports, family activities, etc.) due to shock (if half a day, indicate 0.5)? Exclude any days you have missed	problems relate	d to cardiogenic

Supplementary Material 4. Patient questionnaire to assess quality of life (EQ-5D-5L)

The EQ-5D-5L questionnaire will be administered to patients included prospectively in the study. The Italian validated version of the questionnaire will be employed. The questionnaire will be administered in a paper-based format, with the clinicians supporting the administration phase (e.g., reading out loud the questions to the patients and making their answers). The questionnaire will be administered to patients in Italian, and inputted in English in the Register. The questionnaire will be administered in three time points following Impella or ECMO implantation: i) after 7 days (i.e., while the patient is still in the hospital); ii) after 30 days; iii) after 6 months of follow-up.A formal request to use the EQ-5D-5L questionnaire has been submitted via the official website (ID: 48771).

Questionario sulla salute

Versione italiana per l'Italia

(Italian version for Italy)

VERSIONE PER LA SOMMINISTRAZIONE DA PARTE DELL'INTERVISTATORE/INTERVISTATRICE

Nota per l'intervistatore/intervistatrice: sebbene si debba tenere conto del particolare stile di conversazione dell'intervistatore/intervistatrice, il testo delle istruzioni del questionario dovrà essere seguito il più fedelmente possibile. Nel caso del sistema descrittivo EQ-5D-5L a pagina 2 del questionario, il testo deve essere seguito fedelmente.

Se l'intervistato/a ha difficoltà nello scegliere una risposta, o chiede chiarimenti, l'intervistatore/intervistatrice dovrà ripetere la domanda parola per parola e chiedere all'intervistato/a di rispondere in un modo che sia il più vicino ai suoi pensieri sulla sua salute oggi.

INTRODUZIONE

(Nota per l'intervistatore/intervistatrice: legga quanto segue all'intervistato/a.)

Desideriamo conoscere ciò che pensa della sua salute. Le spiegherò cosa fare man mano che procedo, ma mi interrompa pure nel caso in cui non dovesse comprendere qualcosa o ritenesse che qualcosa non le fosse chiaro. Non ci sono risposte giuste o sbagliate. Siamo interessati solo al suo personale punto di vista.

Per prima cosa, leggerò alcune domande. Ogni domanda ha una scelta di cinque risposte. Mi dica quale risposta descrive meglio la sua salute OGGI.

Non scelga più di una risposta per ogni gruppo di domande.

(Nota per l'intervistatore/intervistatrice: per prima cosa, legga tutte e cinque le opzioni per ogni domanda. Quindi, chieda all'intervistato/a di scegliere quella che pensa si applichi a se stesso/a. Ripeta la domanda e le opzioni se necessario. Contrassegni la casella appropriata sotto ciascun titolo. Potrebbe essere necessario ricordare regolarmente all'intervistato/a che l'intervallo di tempo è OGGI.)

SISTEMA DESCRITTIVO EQ-5D

Per pr	ima cosa, vorremmo chiederle della CAPACITA DI MOVIMENTO	. Direbbe che:				
1.	Non ha difficoltà nel camminare					
2.	Ha <u>lievi</u> difficoltà nel camminare					
3.	Ha <u>moderate</u> difficoltà nel camminare					
4.	Ha <u>gravi</u> difficoltà nel camminare					
5.	Non è in grado di camminare					
Quind	i, vorremmo chiederle della CURA DELLA PERSONA. Direbbe c	he:				
1.	Non ha difficoltà nel lavarsi o vestirsi					
2.	Ha lievi difficoltà nel lavarsi o vestirsi					
3.	Ha moderate difficoltà nel lavarsi o vestirsi					
4.	Ha gravi difficoltà nel lavarsi o vestirsi					
5.	Non è in grado di lavarsi o vestirsi					
Quind	i, vorremmo chiederle delle ATTIVITÀ ABITUALI, per es. lavoro,	studio lavori				
	stici, attività familiari o di svago. Direbbe che:	studio, iuvori				
	Non ha difficoltà nello svolgimento delle attività abituali					
	Ha <u>lievi</u> difficoltà nello svolgimento delle attività abituali	_				
	Ha moderate difficoltà nello svolgimento delle attività abituali	<u> </u>				
	Ha gravi difficoltà nello svolgimento delle attività abituali	_				
	Non è in grado di svolgere le attività abituali	_				
Quind	i, vorremmo chiederle quanto DOLORE O FASTIDIO prova. Dire	bbe che:				
	Non prova alcun dolore o fastidio	_				
	Prova lieve dolore o fastidio	_				
	Prova moderato dolore o fastidio	ā				
	Prova grave dolore o fastidio	_				
	Prova estremo dolore o fastidio	_				
						
Infine, vorremmo chiederle dell'ANSIA O DEPRESSIONE. Direbbe che:						
	Non è ansioso/a o depresso/a					
	È <u>lievemente</u> ansioso/a o depresso/a					
	É moderatamente ansioso/a o depresso/a	_				
	È gravemente ansioso/a o depresso/a	ä				
	È estremamente ansioso/a o depresso/a	_				



- Adesso, vorremmo sapere quanto è buona o cattiva la sua salute OGGI.
- Vorremmo che immaginasse una linea verticale numerata da 0 a 100.

(Nota per l'intervistatore/intervistatrice: in caso di intervista faccia a faccia, mostrare all'intervistato/a la linea VAS.)

 100 in cima alla linea rappresenta la migliore salute che può immaginare.


0 in fondo alla linea rappresenta la <u>peggiore</u> salute che può immaginare.

 Vorrei che ora mi indicasse un punto sulla linea per indicare com'è la sua salute OGGI.

(Nota per l'intervistatore/intervistatrice: contrassegni la linea nel punto che indica la salute dell'intervistato/a OGGI. Ora, scriva il numero indicato sulla linea nella casella sottostante.)

LA SALUTE DELL'INTERVISTATO/A OGGI =

Grazie per il tempo dedicato a rispondere a queste domande.



 $@~2020~EuroQol~Research~Foundation.~EQ-5D^{\text{TM}}~is~a~trade~mark~of~the~EuroQol~Research~Foundation.~Italy~(Italian)~v1.11~trade mark~of~the~EuroQol~Research~Foundation.~Italy~(Italian)~v1.11~trade mark~of~the~EuroQol~Research~of~trade mark~of~the~EuroQol~Research~of~trade mark~of~the~EuroQol~Research~of~trade mark~of~the~EuroQol~Research~of~trade mark~of~trade mark~of~$